APA
AIMT

American Portfolios Advisors’s Aimmune Therapeutics AIMT Stock Holding History

American Portfolios Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-700
Closed -$24.1K – 3146
2020
Q3 		$24.1K Sell
700
-400
-36% -$8.52K ﹤0.01% 1617
2020
Q2 		$18.4K Sell
1,100
-150
-12% -$2.55K ﹤0.01% 1675
2020
Q1 		$18K Buy
1,250
+250
+25% +$6.39K ﹤0.01% 1566
2019
Q4 		$33.5K Hold
1,000
– – ﹤0.01% 1512
2019
Q3 		$20.9K Sell
1,000
-875
-47% -$17.9K ﹤0.01% 1638
2019
Q2 		$39K Sell
1,875
-50
-3% -$1.03K ﹤0.01% 1378
2019
Q1 		$43K Buy
1,925
+1,050
+120% +$24.7K ﹤0.01% 1262
2018
Q4 		$20.9K Buy
875
+150
+21% +$3.88K ﹤0.01% 1351
2018
Q3 		$19.8K Hold
725
– – ﹤0.01% 1492
2018
Q2 		$19.5K Buy
+725
New +$22.2K ﹤0.01% 1464

American Portfolios Advisors's AIMT Position: Q4 2020 in Review

American Portfolios Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 700 shares — an estimated $24.1K sold.

American Portfolios Advisors first reported a position in AIMT in Q2 2018 and held it in 10 quarters. The position peaked at $43K in Q1 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • American Portfolios Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • American Portfolios Advisors sold 700 Aimmune Therapeutics shares in Q4 2020, an estimated $24.1K.
  • American Portfolios Advisors first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 10 quarters.
  • American Portfolios Advisors's Aimmune Therapeutics position peaked at $43K in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on American Portfolios Advisors's 13F filing for Q4 2020, filed 22 Mar 2023.